Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Biostar Expects 2010 Revenues to Climb Higher

publication date: Mar 1, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Biostar Pharmaceuticals expects 2010 revenues of about $70 million and net income of $17 million, excluding non-cash charges. The company is on track to report 2009 revenues of around $52 million, which means the 2010 guidance represents an increase of 35%. About 70% of Biostar’s revenues are generated by Xin Aoxing Oleanolic Acid Capsules, an over-the-counter TCM treatment for hepatitis B. More details...

Stock Symbol: (OTCBB: BSPM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...